menu
    • menu
    [{"orgOrder":0,"company":"Oxilio","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxilio and Quotient Sciences Announce Regulatory Approval for Oxilio\u2019s OXL001 Development Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"OXL001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Oxilio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxilio \/ Quotient Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Oxilio \/ Quotient Sciences"},{"orgOrder":0,"company":"Oxilio","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oxilio Announces Start of Its First Clinical Trial With OXL001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"OXL001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Oxilio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oxilio \/ Oxilio","highestDevelopmentStatusID":"6","companyTruncated":"Oxilio \/ Oxilio"}]

    Find Clinical Drug Pipeline Developments & Deals by Oxilio

    Menu

    Oxilio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oxilio

                            United Kingdom arrow
                            Discovery on Target
                            Not Confirmed

                            Oxilio

                            United Kingdom arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OXL001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Quotient Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oxilio Announces Start of Its First Clinical Trial With OXL001

                            Details : OXL001, has been developed utilising a novel bio-enabling platform technology, it has been taken into clinical studies which gives its immense potential as a pan-cancer therapy.

                            Brand Name : OXL001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 06, 2022

                            Lead Product(s) : OXL001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Quotient Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oxilio

                            United Kingdom arrow
                            Discovery on Target
                            Not Confirmed

                            Oxilio

                            United Kingdom arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OXL001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Quotient Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oxilio and Quotient Sciences Announce Regulatory Approval for Oxilio’s OXL001 Development Program

                            Details : Oxilio has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) for its first Clinical Trial Application (CTA) with OXL001.

                            Brand Name : OXL001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 29, 2022

                            Lead Product(s) : OXL001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Quotient Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth